样式: 排序: IF: - GO 导出 标记为已读
-
Pediatric endoscopy: how can we improve patient outcomes and ensure best practices? Expert Rev. Gastroenterol. Hepatol. (IF 3.9) Pub Date : 2024-03-11 Lisa B. Mahoney, Jeannie S. Huang, Jenifer R. Lightdale, Catharine M. Walsh
Strategies to promote high quality endoscopy in children require consensus around pediatric-specific quality standards and indicators. Using a rigorous guideline development process, the internatio...
-
Towards holistic integrative medicine based management strategy of liver cirrhosis Expert Rev. Gastroenterol. Hepatol. (IF 3.9) Pub Date : 2024-03-07 Deli Zou, Zhiping Yang, Xingshun Qi, Daiming Fan
Published in Expert Review of Gastroenterology & Hepatology (Ahead of Print, 2024)
-
Next-generation therapies for pancreatic cancer Expert Rev. Gastroenterol. Hepatol. (IF 3.9) Pub Date : 2024-02-28 Conor W. Buckley, Eileen M. O’Reilly
Pancreas ductal adenocarcinoma (PDAC) is a frequently lethal malignancy that poses unique therapeutic challenges. The current mainstay of therapy for metastatic PDAC (mPDAC) is cytotoxic chemothera...
-
Endoscopic ultrasound-guided radiofrequency ablation of pancreatic insulinoma: a state of the art review Expert Rev. Gastroenterol. Hepatol. (IF 3.9) Pub Date : 2024-02-21 Jahnvi Dhar, Jayanta Samanta, Zaheer Nabi, Manik Aggarwal, Antonio Facciorusso, Maria Cristina Conti Bellocchi, Stefano Francesco Crinò
Insulinomas are the most common functional pancreatic neuroendocrine tumors (PNETs) that lead to incapacitating hypoglycemia. Guidelines recommend surgical resection as the mainstay of management. ...
-
An update on improving long-term outcomes for patients with chronic pancreatitis post-surgery Expert Rev. Gastroenterol. Hepatol. (IF 3.9) Pub Date : 2024-02-20 Alberto Zorzi, Pietro Campagnola, Antonio Amodio, Federico Caldart, Nicolo De Pretis, Luca Frulloni
Chronic pancreatitis is a common disease that severely impairs patients’ quality of life, mainly due to abdominal pain. Medical therapy alone is rarely effective to treat pain and interventional pr...
-
Development and validation of modified Liaoning score for predicting the prognosis of liver cirrhosis: a retrospective, international multicenter, observational study Expert Rev. Gastroenterol. Hepatol. (IF 3.9) Pub Date : 2024-02-16 Xiaoting Song, Fernando Gomes Romeiro, Jing Wang, Yue Yin, Cyriac Abby Philips, Xinyi Yang, Xiaofeng Liu, Wenming Wu, Marcos Vinícius Tiveli Bernardinelli, Roger Santos de Souza, Arif Hussain Theruvath, Su Lin, Xingshun Qi
Liaoning score has been developed and validated to predict the risk of esophageal varices in liver cirrhosis. This study aimed to further modify the Liaoning score by combining clinical and laborat...
-
Impact of the COVID-19 pandemic on hospitalizations with hepatocellular carcinoma in the United States Expert Rev. Gastroenterol. Hepatol. (IF 3.9) Pub Date : 2024-02-14 Peter Konyn, Brandon J. Perumpail, Karn Wijarnpreecha, George Cholankeril, Aijaz Ahmed, Donghee Kim
We studied the temporal trends of hepatocellular carcinoma (HCC)-related hospitalizations and potential predictors of in-hospital mortality around the COVID-19 pandemic.Using the International Clas...
-
Correction Expert Rev. Gastroenterol. Hepatol. (IF 3.9) Pub Date : 2024-02-05
Published in Expert Review of Gastroenterology & Hepatology (Ahead of Print, 2024)
-
Comparative effectiveness of warfarin in cirrhotic patients with non-symptomatic portal vein thrombosis:a multicenter, randomized controlled trial Expert Rev. Gastroenterol. Hepatol. (IF 3.9) Pub Date : 2024-01-18 Shenxin Lu, Jie Chen, Rui Zhang, Tiancheng Luo, Lili Ma, Pengju Xu, Hong Ding, Xiaoqing Zeng, Bing Wu, Yihai Shi, Chenghai Liu, Yongping Mu, Shiyao Chen, Jian Wang
The effectiveness and risks of anticoagulant therapy in cirrhotic patients with non-symptomatic portal vein thrombosis(PVT) remain unclear. We conducted a multicenter, Zelen-designed randomized con...
-
To STRIDE or not to STRIDE: a critique of “treat to target” in Crohn´s disease Expert Rev. Gastroenterol. Hepatol. (IF 3.9) Pub Date : 2024-01-17 Klaus R. Herrlinger, Eduard F. Stange
The STRIDE consensus suggested to focus on mucosal healing, based on biomarkers and endoscopy, in addition to clinical endpoints as treatment target. This narrative review provides a critique of th...
-
A systematic review and meta-analysis on GERD after OAGB: rate, treatments, and success Expert Rev. Gastroenterol. Hepatol. (IF 3.9) Pub Date : 2024-01-17 Amir Hossein Davarpanah Jazi, Shahab Shahabi, Erfan Sheikhbahaei, Salvatore Tolone, Mehdi El Skalli, Ali Kabir, Rohollah Valizadeh, Mohammad Kermansaravi
This review aims to investigate the gastroesophageal reflux disease (GERD) as one of the important concerns for both surgeons and patients after one anastomosis gastric bypass (OAGB).PubMed, Scopus...
-
Preoperative endoscopic ultrasound-guided biliary drainage for primary drainage in obstructive jaundice Expert Rev. Gastroenterol. Hepatol. (IF 3.9) Pub Date : 2024-01-17 Shuntaro Mukai, Takao Itoi
Endoscopic transpapillary approach by endoscopic retrograde cholangiopancreatography (ERCP) is the established technique for preoperative biliary drainage (PBD). Recently, endoscopic ultrasound-gui...
-
Evaluating the molecular and genetic mechanisms underlying gut motility disorders Expert Rev. Gastroenterol. Hepatol. (IF 3.9) Pub Date : 2024-01-17 Atchariya Chanpong, Maria M. Alves, Elena Bonora, Roberto De Giorgio, Nikhil Thapar
Gastrointestinal (GI) motility disorders comprise a wide range of different diseases affecting the structural or functional integrity of the GI neuromusculature. Their clinical presentation and bur...
-
Diagnosis and management of pancreatic insufficiency in patients with gastrectomy due to cancer or gastric ulcers: a virtual roundtable expert discussion Expert Rev. Gastroenterol. Hepatol. (IF 3.9) Pub Date : 2024-01-17 Daniel Croagh, Christoph W. Michalski, Mark I. van Berge Henegouwen, Sergio Alfieri
Pancreatic exocrine insufficiency (PEI) is common after gastric resection for cancer or ulcers but is under-recognized and undertreated. Although pancreatic enzyme replacement therapy (PERT) is the...
-
Risankizumab to treat moderately to severely active Crohn’s disease in adults: an evaluation of trials and data Expert Rev. Gastroenterol. Hepatol. (IF 3.9) Pub Date : 2024-01-17 Amanda M. Johnson, Edward V. Loftus Jr.
Risankizumab is a humanized monoclonal antibody that selectively inhibits interleukin (IL)-23. It is approved for the treatment of moderate-to-severe plaque psoriasis, psoriatic arthritis, and more...
-
Recent advances in the treatment of gastrointestinal motility disorders in children Expert Rev. Gastroenterol. Hepatol. (IF 3.9) Pub Date : 2024-01-17 Andreia Florina Nita, Atchariya Chanpong, Kornilia Nikaki, Anna Rybak, Nikhil Thapar, Osvaldo Borrelli
Pediatric gastrointestinal motility disorders represent some of the most challenging clinical conditions with largely undefined pathogenetic pathways and therefore limited therapeutic options. Here...
-
Managing complications of chronic pancreatitis: a guide for the gastroenterologist Expert Rev. Gastroenterol. Hepatol. (IF 3.9) Pub Date : 2024-01-17 Gabriele Capurso, Matteo Tacelli, Giuseppe Vanella, Ruggero Ponz de Leon Pisani, Giuseppe Dell’Anna, Martina Abati, Roberto Mele, Gaetano Lauri, Afrodita Panaitescu, Rubino Nunziata, Piera Zaccari, Livia Archibugi, Paolo Giorgio Arcidiacono
Chronic pancreatitis is a heterogeneous and complex syndrome that, in most cases, causes pain as a cardinal symptom and affects both the morphology and function of the pancreas, leading to several ...
-
Recent developments in diagnosing bile acid diarrhea Expert Rev. Gastroenterol. Hepatol. (IF 3.9) Pub Date : 2024-01-17 Camille Lupianez-Merly, Saam Dilmaghani, Michael Camilleri
Bile acid diarrhea (BAD) commonly causes chronic diarrhea. Symptoms may be mistaken for disorders of gut brain interaction. Due to the lack of widely available diagnostic tests and poor recognition...
-
Noninvasive electrical neuromodulation for gastrointestinal motility disorders Expert Rev. Gastroenterol. Hepatol. (IF 3.9) Pub Date : 2024-01-17 Jieyun Yin, Jiande DZ Chen
Gastrointestinal motility disorders are highly prevalent without satisfactory treatment. noninvasive electrical neuromodulation is an emerging therapy for treating various gastrointestinal motility...
-
Imaging in pediatric disorders of the gut-brain interactions: current best practice and future directions Expert Rev. Gastroenterol. Hepatol. (IF 3.9) Pub Date : 2024-01-17 Shaman Rajindrajith, Wathsala Hathagoda, Eranga Ganewatte, Niranga Manjuri Devanarayana, Nikhil Thapar, Marc Benninga
Disorders of Gut-Brain Interactions (DGBI) are a common clinical problem in children and pose significant challenges to the attending pediatrician. Radiological investigations are commonly ordered ...
-
Nosocomial spontaneous bacterial peritonitis is associated with high mortality – a systematic review and meta-analysis Expert Rev. Gastroenterol. Hepatol. (IF 3.9) Pub Date : 2024-01-17 Mubeen Khan Mohammed Abdul, Karim T. Osman, Joseph M. Cappuccio, Carol Spencer, Sanjaya K. Satapathy
It is unclear if Nosocomial Spontaneous Bacteria Peritonitis (NSBP) is associated with higher mortality compared with community acquired spontaneous bacterial peritonitis.Database search from incep...
-
Securing the diagnosis of HRS-AKI: implications for current therapies Expert Rev. Gastroenterol. Hepatol. (IF 3.9) Pub Date : 2024-01-17 Arpan Mohanty, Andrés Cárdenas
Hepatorenal syndrome (HRS)-acute kidney injury (HRS-AKI) is a specific type of kidney injury seen in patients with cirrhosis and ascites and is associated with high mortality and morbidity. It is c...
-
An overview of the efficacy, safety, and predictors of achalasia treatments Expert Rev. Gastroenterol. Hepatol. (IF 3.9) Pub Date : 2024-01-17 Elise M. Wessels, Gwen M.C. Masclee, Albert J. Bredenoord
Achalasia is a rare esophageal motility disorder characterized by abnormal esophageal peristalsis and the inability of the lower esophageal sphincter to relax, resulting in poor esophageal emptying...
-
Development and validation of a risk model to predict the progression of ulcerative colitis patients to acute severe disease within one year Expert Rev. Gastroenterol. Hepatol. (IF 3.9) Pub Date : 2024-01-17 Jie Chen, Yue Zhang, Qiong Guo, Tianqi Ren, Nana Tang, Han Chen, Hongjie Zhang
Acute severe ulcerative colitis (ASUC) is strongly associated with poor prognosis. We aimed to establish and validate a model predicting ASUC occurrence within 1 year after ulcerative colitis(UC) d...
-
Influence of metabolic dysfunction-associated fatty liver disease on the prognosis of patients with HBV-related acute-on-chronic liver failure Expert Rev. Gastroenterol. Hepatol. (IF 3.9) Pub Date : 2024-01-02 Rui-Min Lai, Li-Xi Yao, Shan Lin, Jia-Hui Zhou, Bing-Ping Liu, Zhao-Yi Liang, Tianbin Chen, Jia-Ji Jiang, Qi Zheng, Yueyong Zhu
Metabolic-associated fatty liver disease (MAFLD) has clinical relevance in patients with acute-on-chronic liver failure (ACLF). We investigated the association between MAFLD and prognosis in patien...
-
Optimizing ambulatory reflux monitoring: current findings and future directions Expert Rev. Gastroenterol. Hepatol. (IF 3.9) Pub Date : 2023-12-25 Dhweeja Dasarathy, Michael Vaezi, Dhyanesh Patel
Gastroesophageal reflux disease (GERD) is the most common diagnosis seen in outpatient gastroenterology clinics. The diagnosis is made by a variable combination of symptoms, response to acid suppre...
-
Trends and challenges in home enteral feeding methods for children with gastrointestinal disorders: an expert review on bolus feeding delivery methods Expert Rev. Gastroenterol. Hepatol. (IF 3.9) Pub Date : 2023-11-29 Claudio Romano, Paolo Lionetti, Maria Immacolata Spagnuolo, Sergio Amarri, Antonella Diamanti, Elvira Verduci, Antonella Lezo, Gatti Simona
New evidence supports the benefits of bolus feeding for children receiving home enteral feeding (HEN). Current home methods of bolus feeding have certain limitations, particularly in mobile or rest...
-
Relief from behind: enemas, the back door enforcement to help treating chronic constipation in adults Expert Rev. Gastroenterol. Hepatol. (IF 3.9) Pub Date : 2023-11-23 Gabrio Bassotti
Chronic constipation is a frequent symptom encountered in the daily clinical practice. The treatment of this condition mainly relies on the use of laxatives. However, patients’ satisfaction with th...
-
ERCP-related adverse events: incidence, mechanisms, risk factors, prevention, and management Expert Rev. Gastroenterol. Hepatol. (IF 3.9) Pub Date : 2023-11-23 Angelica Rivas, Simran Pherwani, Rachid Mohamed, Zachary L. Smith, B. Joseph Elmunzer, Nauzer Forbes
Endoscopic retrograde cholangiopancreatography (ERCP) is a commonly performed procedure for pancreaticobiliary disease. While ERCP is highly effective, it is also associated with the highest advers...
-
Small bowel imaging in inflammatory bowel disease: updates for 2023 Expert Rev. Gastroenterol. Hepatol. (IF 3.9) Pub Date : 2023-11-23 Maira Hameed, Stuart A Taylor
Cross-sectional imaging techniques including MR and CT enterography and ultrasound are integral to Crohn’s disease management, accurate, responsive, and well tolerated. They assess the full thickne...
-
Hemostatic powders and gels in gastrointestinal endoscopy: current perspective and future recommendations Expert Rev. Gastroenterol. Hepatol. (IF 3.9) Pub Date : 2023-11-23 Jahnvi Dhar, Daryl Ramai, Jayanta Samanta, Antonio Facciorusso
Published in Expert Review of Gastroenterology & Hepatology (Vol. 17, No. 11, 2023)
-
Terlipressin in the management of adults with hepatorenal syndrome-acute kidney injury (HRS-AKI) Expert Rev. Gastroenterol. Hepatol. (IF 3.9) Pub Date : 2023-11-23 Anand V. Kulkarni, Jason Lee, K. Rajender Reddy
Kidney is the most common extra-hepatic organ involved in patients with advanced liver cirrhosis and acute-on-chronic liver failure. Hepatorenal syndrome-acute kidney injury (HRS-AKI) accounts for ...
-
Adenoma detection rate in colonoscopy: how can it be improved? Expert Rev. Gastroenterol. Hepatol. (IF 3.9) Pub Date : 2023-11-23 Marco Spadaccini, Alessandro Schilirò, Paranjay Sharma, Alessandro Repici, Cesare Hassan, Antonio Voza
The introduction of widespread colonoscopy screening programs has helped in decreasing the incidence of Colorectal Cancer (CRC). However, ‘back-to-back’ colonoscopies revealed relevant percentage o...
-
A role for immune modulation in achieving functional cure for chronic hepatitis B among current changes in the landscape of new treatments Expert Rev. Gastroenterol. Hepatol. (IF 3.9) Pub Date : 2023-11-23 Béatrice Laupèze, Ventzislav Vassilev, Selim Badur
Chronic hepatitis B (CHB) is rarely cured using available treatments. Barriers to cure are: 1) persistence of reservoirs of hepatitis B virus (HBV) replication and antigen production (HBV DNA); 2) ...
-
Virtual reality interventions to reduce psychological distress during colonoscopy: a rapid review Expert Rev. Gastroenterol. Hepatol. (IF 3.9) Pub Date : 2023-11-23 Mahdi Shamali, Peter Vilmann, Niels René Johansen, Hanne Konradsen
Colonoscopy can cause psychological distress in patients, consequently discouraging patients from undergoing an unpleasant procedure or reducing compliance with follow-up examinations. This rapid r...
-
Performance of GALAD score and serum biomarkers for detecting NAFLD-related HCC: a systematic review and network meta-analysis Expert Rev. Gastroenterol. Hepatol. (IF 3.9) Pub Date : 2023-11-23 Han Li, Hui Liu, Lun-Jie Yan, Zi-Niu Ding, Xiao Zhang, Guo-Qiang Pan, Cheng-Long Han, Bao-Wen Tian, Si-Yu Tan, Zhao-Ru Dong, Dong-Xu Wang, Yu-Chuan Yan, Tao Li
The incidence of nonalcoholic fatty liver disease (NAFLD)-related hepatocellular carcinoma (HCC) is increasing globally. We aimed to assess the performance of alpha-fetoprotein (AFP), AFP-L3, des-g...
-
Towards a better diagnosis of gastro esophageal reflux disease Expert Rev. Gastroenterol. Hepatol. (IF 3.9) Pub Date : 2023-10-24 Mentore Ribolsi, Edoardo Savarino
GERD is a common disorder and is characterized by the presence of typical or atypical symptoms. In GERD patients, the presence of mucosal alterations in endoscopy is detected in up to 30% of indivi...
-
The role of microRNAs in the different phases of liver regeneration Expert Rev. Gastroenterol. Hepatol. (IF 3.9) Pub Date : 2023-10-24 Anna Emilia Kern, Gregor Ortmayr, Alice Assinger, Patrick Starlinger
Since the first discovery of microRNAs (miRs) extensive evidence reveals their indispensable role in different patho-physiological processes. They are recognized as critical regulators of hepatic r...
-
Efficacy and safety of tolvaptan in cirrhotic patients: a systematic review and meta-analysis of randomized controlled trials Expert Rev. Gastroenterol. Hepatol. (IF 3.9) Pub Date : 2023-10-24 Lu Chai, Zhe Li, Ting Wang, Ran Wang, Kanokwan Pinyopornpanish, Gang Cheng, Xingshun Qi
Tolvaptan has been approved for the management of cirrhosis-related complications according to the Japanese and Chinese practice guidelines, but not the European or American practice guidelines in ...
-
Managing pediatric Crohn’s disease: recent insights Expert Rev. Gastroenterol. Hepatol. (IF 3.9) Pub Date : 2023-10-24 Katherine Baldwin, Victoria Grossi, Jeffrey S. Hyams
Children and adolescents with Crohn’s disease present unique challenges due to extensive disease at diagnosis and the effect of bowel inflammation on growth. Historical approaches with corticostero...
-
Stratification of obesity phenotypes to optimize future therapy (SOPHIA) Expert Rev. Gastroenterol. Hepatol. (IF 3.9) Pub Date : 2023-10-24 Abd A Tahrani, Marina Panova-Noeva, Nanette C Schloot, Anita M Hennige, Jeannette Soderberg, Joe Nadglowski, Lisa Tarasenko, Nadia N Ahmad, Barbara SC Sleypen, Rafael Bravo, Werd Al-Najim, Carel W le Roux
Obesity is considered a poor lifestyle choice. ‘Obesity’ is not a sufficient definition for patients, any more than ‘cancer’ or ’arthritis’ would be. A major obstacle is the lack of understanding o...
-
Recommendations for the management of opioid-induced constipation - how to improve usability in clinical practice Expert Rev. Gastroenterol. Hepatol. (IF 3.9) Pub Date : 2023-10-24 Tina Okdahl, Anton Emmanuel, Bart Morlion, Adam Farmer, Giustino Varrassi, Asbjørn Mohr Drewes
Opioid-induced constipation remains undertreated despite effective and safe treatment options exists. Previous guidelines have only been partially effective in improving management, possibly due to...
-
Protective and therapeutic potential of melatonin against intestinal diseases: updated review of current data based on molecular mechanisms Expert Rev. Gastroenterol. Hepatol. (IF 3.9) Pub Date : 2023-10-24 Saeed Mehrzadi, Mohammad Sheibani, Fereshteh Koosha, Nazila Alinaghian, Mohammad Hossein Pourhanifeh, Seid Amir Pasha Tabaeian, Russel J. Reiter, Azam Hosseinzadeh
Intestinal diseases, a leading global cause of mortality and morbidity, carry a substantial socioeconomic burden. Small and large intestines play pivotal roles in gastrointestinal physiology and fo...
-
The necessity and safety of simultaneous cholecystectomy during gastric surgery for patients with asymptomatic cholelithiasis Expert Rev. Gastroenterol. Hepatol. (IF 3.9) Pub Date : 2023-10-24 Tianxiang Jiang, Haidong Zhang, Xiaonan Yin, Zhaolun Cai, Zhou Zhao, Mingchun Mu, Baike Liu, Chaoyong Shen, Bo Zhang, Yuan Yin
The incidence of cholelithiasis is higher among individuals who have undergone gastric surgery. The benefits of concomitant gallbladder removal in asymptomatic gallstone patients remain uncertain. ...
-
Combining Anti-epidermal Growth Factor Receptor (EGFR) Therapy with Immunotherapy in Metastatic Colorectal Cancer (mCRC) Expert Rev. Gastroenterol. Hepatol. (IF 3.9) Pub Date : 2023-09-13 Feng Xiong, Yu-Wen Zhou, Ya-Ting Hao, Gui-Xia Wei, Xiao-Rong Chen, Meng Qiu
ABSTRACT Introduction Monoclonal antibodies binding the EGFR, such as cetuximab and panitumumab, have been extensively used as targeted therapy for the treatment of mCRC. However, in clinical practice, it has been found that these treatment options have some limitations and fail to fully exploit their immunoregulatory activities. Meanwhile, because of the limited effects of current treatments, immunotherapy
-
Algorithms for early detection of silent liver fibrosis in the primary care setting – a scoping review Expert Rev. Gastroenterol. Hepatol. (IF 3.9) Pub Date : 2023-09-11 Line Ravndal, Katrine P. Lindvig, Ellen L. Jensen, Anita Sunde, Damoun Nassehi, Maja Thiele, Aleksander Krag, Svein Kjosavik
Fatty liver disease affects almost 30% of the adult population worldwide. Most patients are asymptomatic, and there is not a linear relationship between exposure to risk factors and the risk of dev...
-
Mistakes in managing hepatocellular carcinoma and how to avoid them: a narrative review Expert Rev. Gastroenterol. Hepatol. (IF 3.9) Pub Date : 2023-09-07 Madunil Anuk Niriella, Uditha Dassanayake, H Janaka de Silva
Hepatocellular carcinoma (HCC) is the most common liver-related cancer and the third leading cause of worldwide cancer-related mortality.There have been many updated guidelines on the management of...
-
Alagille syndrome: understanding the genotype-phenotype relationship and its potential therapeutic impact Expert Rev. Gastroenterol. Hepatol. (IF 3.9) Pub Date : 2023-09-05 Jennifer Halma, Henry C. Lin
Alagille syndrome (ALGS) is an autosomal dominant, multisystem genetic disorder with wide phenotypic variability caused by mutations in the Notch signaling pathway, specifically from mutations in e...
-
Therapeutics for Clostridioides difficile infection: molecules and microbes Expert Rev. Gastroenterol. Hepatol. (IF 3.9) Pub Date : 2023-08-25 Sahil Khanna, Elida Voth
Clostridioides difficile infection (CDI) is a major healthcare problem in the developed world, and effective management of recurrent infection remains one of the biggest challenges. Several advance...
-
A spotlight on intestinal permeability and inflammatory bowel diseases Expert Rev. Gastroenterol. Hepatol. (IF 3.9) Pub Date : 2023-08-22 Timo Rath, Raja Atreya, Markus F. Neurath
The intestinal barrier is a multi-faced structure lining the surface of the intestinal mucosa of the GI tract. To exert its main functions as a physical and immunological defense barrier, several c...
-
Bone health in inflammatory bowel disease Expert Rev. Gastroenterol. Hepatol. (IF 3.9) Pub Date : 2023-08-20 Hao Wei, Yihan Zhao, Lisha Xiang
Inflammatory bowel disease (IBD) is a chronic disease characterized by the presence of systemic inflammation, manifesting not only as gastrointestinal symptoms but also as extraintestinal bone comp...
-
Managing pain in irritable bowel syndrome: current perspectives and best practice Expert Rev. Gastroenterol. Hepatol. (IF 3.9) Pub Date : 2023-08-08 Joost Algera, Jenny Lövdahl, Jessica Sjölund, Navkiran Thind Tornkvist, Hans Törnblom
Irritable bowel syndrome (IBS) is characterized by chronic symptoms (>6 months) of abdominal pain in combination with a disturbed bowel habit. There is an association between the intensity of abdom...
-
Electrosurgical unit in GI endoscopy: the proper settings for practice Expert Rev. Gastroenterol. Hepatol. (IF 3.9) Pub Date : 2023-08-04 Anuraag Jena, Shubham Jain, Sridhar Sundaram, Anupam Kumar Singh, Sanjay Chandnani, Pravin Rathi
ABSTRACT Introduction Electrosurgical unit (ESU) is integral to the endoscopy unit. The proper knowledge of the Mode with setting is essential for good therapeutic outcomes and the safety of the patients. Areas covered ESU generates high-frequency electric current, which could perform cutting and coagulation for various therapeutic interventions. We review the proper settings for common endoscopic
-
Risk factors for recurrent common bile duct stones: a systematic review and meta-analysis Expert Rev. Gastroenterol. Hepatol. (IF 3.9) Pub Date : 2023-08-03 Ningyuan Wen, Yaoqun Wang, Yulong Cai, Guilin Nie, Sishu Yang, Shaofeng Wang, Xianze Xiong, Bei Li, Jiong Lu, Nansheng Cheng
Common bile duct stones (CBDS) have a reported recurrence rate of 4%-24% after stone extraction. The most commonly applied stone extraction method is endoscopic cholangiopancreatography (ERCP). We ...
-
Primary biliary cholangitis: primary autoimmune disease or primary secretory defect Expert Rev. Gastroenterol. Hepatol. (IF 3.9) Pub Date : 2023-08-03 Annarosa Floreani, Daniela Gabbia, Sara De Martin
Primary biliary cholangitis (PBC) is a chronic cholestatic liver disease characterized by the immune-mediated destruction of small and medium intrahepatic bile ducts, involving predominantly female...
-
A narrative review on the diagnosis and management of constipation in infants Expert Rev. Gastroenterol. Hepatol. (IF 3.9) Pub Date : 2023-08-01 Laurine Steurbaut, Elvira Ingrid Levy, Charlotte De Geyter, Stefanie Buyse, Yvan Vandenplas
ABSTRACT Introduction Functional constipation is one of the common disorders of gut–brain interaction in infancy, and decreases the quality of life of infants and parents. Areas covered Relevant articles up to November 2022 were reviewed. We searched in PubMed, Google Scholar, and MEDLINE for guidelines, position papers, reviews, and randomized controlled trials on infant constipation. Expert opinion
-
The meaning of R1 resection after endoscopic removal of gastric, duodenal and rectal neuroendocrine tumors Expert Rev. Gastroenterol. Hepatol. (IF 3.9) Pub Date : 2023-07-31 Gianluca Esposito, Elisabetta Dell’Unto, Irene Ligato, Matteo Marasco, Francesco Panzuto
ABSTRACT Introduction Well-differentiated gastric, duodenal, and rectal neuroendocrine neoplasms (NETs) are rare diseases usually managed by endoscopic treatment. Although several endoscopic techniques are available, the number of patients with incomplete (R1) resection is significant. Areas covered This review focuses on the meaning of incomplete R1 findings after endoscopic resection in type I gastric
-
Strengths and limitations of risk stratification tools for patients with upper gastrointestinal bleeding: a narrative review Expert Rev. Gastroenterol. Hepatol. (IF 3.9) Pub Date : 2023-07-31 Ali A. Alali, Antoine Boustany, Myriam Martel, Alan N. Barkun
ABSTRACT Introduction Despite advances in the management of patients with upper gastrointestinal bleeding (UGIB), associated morbidity and mortality remain significant. Most patients, however, will experience favorable outcomes without a need for hospital-based interventions. Risk assessment scores may assist in such early risk-stratification. These scales may optimize identification of low-risk patients
-
Familial intestinal polyposis and device assisted enteroscopy: where do we stand? Expert Rev. Gastroenterol. Hepatol. (IF 3.9) Pub Date : 2023-07-29 Giuseppe Losurdo, Milena Di Leo, Salvatore Rizzi, Ilaria Lacavalla, Francesca Celiberto, Andrea Iannone, Maria Rendina, Enzo Ierardi, Giuseppe Iabichino, Luca De Luca, Alfredo Di Leo
ABSTRACT Introduction Hereditary polyposis syndromes are a group of inherited disorders associated with a high risk of developing colorectal cancer. The best known ones are familial adenomatous polyposis (FAP), Peutz-Jeghers (PJS), juvenile polyposis and Cowden syndromes, as well as conditions predisposing to cancer, such as Lynch syndrome. Some of them are characterized by an increased risk of small
-
The challenging role of micro-RNAs in non-alcoholic fatty liver disease in children with obesity: is it time for a new era? Expert Rev. Gastroenterol. Hepatol. (IF 3.9) Pub Date : 2023-07-29 Mario Bartiromo, Michele Nardolillo, Serena Ferrara, Giuseppina Russo, Emanuele Miraglia Del Giudice, Anna Di Sessa
ABSTRACT Introduction As the pediatric obesity epidemic, nonalcoholic fatty liver disease (NAFLD) has become the most common chronic liver disease in childhood. Pediatric NAFLD pathophysiology is tangled and still unclear, but insulin resistance (IR), genetics, epigenetics, oxidative stress, and inflammation act as key players. Due to the increased cardiometabolic risk of these patients, several biomarkers